Myriad Pharmaceuticals Inc Myrx Financial And Strategic Analysis Review --- Aarkstore Enterprise

Myriad Pharmaceuticals, Inc

Myriad Pharmaceuticals, Inc. (MYRX) - Financial and Strategic Analysis Review

Myriad Pharmaceuticals, Inc. (Myriad Pharmaceuticals) is a pharmaceutical company, engaged in the discovery, development, and commercialization of small molecule drug candidates for the medical conditions of cancer and HIV. Its clinical stage pipeline products include Azixa (MPC-6827), MPC-3100, MPC-4326. Azixa is an investigational drug candidate being developed in Phase II clinical trials for the treatment of patients with GBM and advanced primary and metastatic tumors. MPC-3100 is in Phase I clinical study for the treatment of Cancer and MPC-4326 is in Phase II study for HIV.

Myriad Pharmaceuticals, Inc. Key Recent Developments

Feb 16, 2010: Myriad Pharmaceuticals Q2 2009 Net Loss Narrows Down

Dec 01, 2009: Myriad Starts Phase IIb Study Of HIV Drug

Nov 12, 2009: Myriad Reports Net Loss Of $10.6 Million For Q1 Fiscal 2010

Oct 13, 2009: Myriad Identifies IND Candidate For Treatment Of Cancer, Obesity, Diabetes

This comprehensive SWOT profile of Myriad Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Myriad Pharmaceuticals, Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).

The profile contains critical company information including*,

- Business description A detailed description of the companys operations and business divisions.

- Corporate strategy Analysts summarization of the companys business strategy.

- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.

- Company history Progression of key events associated with the company.

- Major products and services A list of major products, services and brands of the company.

- Key competitors A list of key competitors to the company.

- Key employees A list of the key executives of the company.

- Executive biographies A brief summary of the executives employment history.

- Key operational heads A list of personnel heading key departments/functions.

- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

For more information, please visit :

http://www.aarkstore.com/reports/Myriad-Pharmaceuticals-Inc-MYRX-Financial-and-Strategic-Analysis-Review-51779.html

by: Aarkstore Enterprise

POST COMMENT

Wholesale Dvds: Where You Can Get Them Genexine Co., Ltd. (95700) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Aarkstore Enterprise--indoco Remedies Limited (532612) - Financial And Strategic Analysis Review Zhongtian International Limited (2379) - Financial And Strategic Analysis Review --- Aarkstore Giaconda Limited (gia) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Cytodyn, Inc. (cydy) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Intellect Neurosciences, Inc. (ilns) - Financial And Strategic Analysis Review --- Aarkstore Qrxpharma Limited (qrx) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Omeros Corporation (omer) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Sosei Co. Ltd. (4565) - Financial And Strategic Analysis Review --- Aarkstore Enterprise Laboratorios Farmaceuticos Rovi, S.a. (rovi) - Financial And Strategic Analysis Review --- Aarkstore Biostar Pharmaceuticals, Inc. (bspm) - Financial And Strategic Analysis Review --- Aarkstore Cryo-save Group N.v. (cryo) - Financial And Strategic Analysis Review --- Aarkstore Enterprise